Compare IOVA & LU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IOVA | LU |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2008 | 2020 |
| Metric | IOVA | LU |
|---|---|---|
| Price | $4.09 | $1.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 1 |
| Target Price | ★ $9.00 | $2.00 |
| AVG Volume (30 Days) | ★ 13.1M | 887.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.74 | N/A |
| Revenue Next Year | $40.31 | $22.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $1.68 |
| 52 Week High | $5.63 | $4.57 |
| Indicator | IOVA | LU |
|---|---|---|
| Relative Strength Index (RSI) | 61.90 | 27.87 |
| Support Level | $2.05 | N/A |
| Resistance Level | $4.27 | $2.77 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 87.50 | 14.99 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.